(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/211380 A1

(51) International Patent Classification:
C07D 519/00 (2006.01) *A61P 35/00* (2006.01)
A61K 31/497 (2006.01)

(21) International Application Number:
PCT/US2021/026611

(22) International Filing Date:
09 April 2021 (09.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/011,701 17 April 2020 (17.04.2020) US
63/151,354 19 February 2021 (19.02.2021) US

(71) Applicant: **LOXO ONCOLOGY, INC.** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **BHARDWAJ, Rajni Miglani**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **KERR, Mark Steven**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **KJELL, Douglas Patton**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **MERRITT, Jeremy Miles**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SELBO, Jon Gordon**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **VISWANATH, Shekhar Krishna**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **CRAWFORD, Bradley W.** et al.; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CRYSTALLINE RET INHIBITOR




Figure 1

(57) Abstract: Provided herein is a crystalline form of selpercatinib useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders, and methods of making this crystalline form.

WO 2021/211380 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*